Intensive chemotherapy of diffuse large b-cell lymphosarcoma in a female patient with chronic renal failure and afunctional left kidney

Full Text

Интенсивная химиотерапия диффузной в-крупноклеточной лимфосаркомы у больной с хронической почечной недостаточностью и афункциональной левой почкой. -


  1. Harris N. L., Jaffe Е. S., Diebold J. et al. World Health Organization classification diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee meeting. - Airline House, Virginia, November 1997. J. Clin. Oncol. 1999; 17 (12): 3835-3849.
  2. Harris N. L., Jaffe E. S., Stein H. et al. A revised European-American classification of lymphoid neoplasm's: A proposal from The International Lymphoma Study Group. Blood 1994; 84 (5): 1301-1392.
  3. Воробьев А. И. (ред.) Руководство по гематологии. М.: Ньюдиамед; 2003; т. 2: 55, 98-100.
  4. Бабичева Л. Г., Поддубная И. В. Дополнительные клинико-лабораторные факторы прогноза при диффузной В-крупноклеточной лимфоме. Соврем. онкол. 2006; 8(1): 37-41.
  5. Abramson J. S., Shipp M. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106 (4): 1164-1174.
  6. Alizadeh A. A., Elsen M. В., Davis R. E. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
  7. Barrans S., Carter I., Morgan G. J. et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99 (4): 1136-1142.
  8. Barrans S., Connor S., Evans P. et al. Rearrangement of the BCL-6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br. J. Haematol. 2002; 117: 322-332.
  9. Barrans S., Evans P., Connor S. et al. The t(14; 18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin. Cancer Res. 2003; 9: 2133-2139.
  10. Rosenwald A., Wright G., Chan W. C. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 2002; 346: 1937-1947.
  11. Shipp M. A., Ross K. N., Tramayo P. et al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat. Med. 2002; 8 (1): 68-74.
  12. Chung R., Lai R., Wei P. et al. Concordant but discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007; 110 (4): 1278-1282.
  13. Falini В., Fizzotti M., Pucciarini A. et al. A monoclonal antibody (MUM1) detects expression of the MUM1/IRF4 protein in a subset of germinal center В cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
  14. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N. Engl. J. Med. 2005; 353: 1197-1205.
  15. Balzarotti M., Spina M., Sarina B. et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann. Oncol. 2002; 13 (9): 1341-1346.
  16. Brusamolino E., Rusconi C., Montalbetti L. et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-502.
  17. Fisher R. Treatment of diffuse large B-cell lymphomas. Semin. Hematol. 2006; 34: 205.
  18. Coiffier В., Gisselbrecht C., Gaulard P. et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large-B-cell lymphoma. Blood 2003; 6 (6): 1182.
  19. Магомедова А. У., Кравченко С. К., Кременецкая А. М. и др. Модифицированная программа NHL-BFM-90 в лечении больных диффузной В-крупноклеточной лимфосаркомой. Тер. арх. 2006; 10: 44-47.
  20. Pfreundschuh М., Trumper L., Osterborg A. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol. 2006; 7: 379-391.
  21. Freytes C., Loberiza F., Rizzo D. et al. Myeloablative allogenic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104 (12): 3797-3803.
  22. Gisselbrecht C., Lepage E., Molina T. et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J. Clin. Oncol. 2002; 20 (10): 2472-2479.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies